Regarding the treatment patterns, nearly all patients in our study received anti-VEGF monotherapy, while only 5.4% (22/410, N = AMD + PCV of both ethnicities) underwent combination therapy with photodynamic therapy (PDT) plus anti-VEGF. The gene discussed is VEGFA; the disease is age-related macular degeneration.